

# IT STARTS WITH ONE

**JUNE 3-6, 2019 • PHILADELPHIA • #BIO2019**

# Children's Tumor Foundation

## Patients: Empowered Clients




CHILDREN'S  
TUMOR  
FOUNDATION  
ENDING NF  
THROUGH RESEARCH

# Our Focus - Neurofibromatosis



2,5 million patients worldwide!  
NF1, NF2, schwannomatosis  
*Tumors*




# CTF Ambition: 'Now' 'Fast' 'Together'

- Global Connector
- System Disruptor
- De-risker



# Global Connector – value proposition




# System Disruptor: SYNODOS

From:



To:



# De-risker for Pharma

Preclinical  
Test System

NF Clinic  
Network



Target scan  
service

Global:  
Clinicians &  
Patients

Patient owned  
NF registry


Patient  
Advisors/  
Reviewers

Market Model

Global Network  
Conference/  
Workshops

# CTF IMPACT - Selumetinib: Registration trial

## In 70% patients tumor shrink >20%



NEJM 2016,  
375 :2550





# CTF Impact in Numbers

CTF investments from 2010 to 2015, totaling **\$26.6M**

have attracted more than **\$38.4M**  
in follow-up funding

**700**  
registrants at conference

**15,000**  
citations of CTF  
publications this year

**2**  
new NF  
pig models

**54** clinics

**116** preclinical trials

# CTF Impact in Numbers

**1st** partnership with pharma

Over

**100**

Schwannomatosis samples

**6,000**

data sets in  
NF data portal

**6**

cell lines  
open to all!

**40**

labs work together

# THANK YOU



*abakker@ctf.org*